Quantcast
Last updated on April 16, 2014 at 14:14 EDT

Latest Hepatitis C/co-infection with HIV Stories

2011-12-16 13:57:52

Among people recently infected with HIV, immediate antiretroviral therapy (ART) appears preferable to deferring treatment, according to a new study published in the Journal of Infectious Diseases and now available online. Although the benefits of ART during early HIV-1 infection remain unproven, the findings support growing evidence favoring earlier ART initiation. Christine Hogan, MD, of the Medical College of Wisconsin in Milwaukee, led a team of researchers from various institutions to...

2011-12-16 07:00:00

PRINCETON, N.J., Dec. 16, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today that the company will amend the design of the QUANTUM Phase 2b trial of the guanine nucleotide analog PSI-938 and discontinue all treatment arms with a regimen containing PSI-938. There are 235 individuals with hepatitis C virus (HCV) in the study who are receiving treatment with PSI-938 alone or in combination with PSI-7977 or PSI-7977 and ribavirin. During routine safety monitoring, the company...

2011-12-10 01:51:30

Some patients with chronic hepatitis C may benefit from boceprevir / Extent of added benefit still unclear The active ingredient boceprevir has been available since the middle of 2011 as a treatment for chronic hepatitis C of genotype 1. In an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal Products” (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) has now examined to establish whether boceprevir offers added...

2011-12-02 06:30:00

HUDDINGE, Sweden, December 2, 2011 /PRNewswire/ -- Medivir AB (OMX:MVIR), the research-based speciality pharmaceutical company focused on the development of high-value treatments for infectious diseases, announces that its development partner, Tibotec Pharmaceuticals, has entered into an agreement with Bristol-Myers Squibb Company (NYSE:BMY). TMC435, a once daily NS3/4A protease inhibitor (PI) for the treatment of genotype-1 chronic hepatitis C virus (HCV) infection will...

2011-11-16 08:30:00

SAN DIEGO, Nov. 16, 2011 /PRNewswire/ -- Aethlon Medical, Inc., (OTCBB:AEMD) disclosed today that its Chairman and CEO, James A. Joyce, has issued the following letter to shareholders. (Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b) To our Shareholders: Earlier this year, we introduced and began marketing the Aethlon ADAPT(TM) system, a technology platform that intersects the medical device and drug world to establish a new class of therapeutics that allow for the...

2011-11-14 16:11:00

PRINCETON, N.J., Nov. 14, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections, today reported financial results and operational highlights for the fiscal year ended September 30, 2011. At fiscal year end Pharmasset held $166.5 million in cash and cash equivalents and used $21.7 million of our cash and cash equivalents during the fourth quarter of fiscal...

2011-11-08 11:00:00

SAN FRANCISCO and RIDGEFIELD, Conn., Nov. 8, 2011 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced results from two Phase 2 studies evaluating the combination of the company's protease inhibitor, BI 201335, with pegylated interferon (PegIFN) and ribavirin (RBV) in treatment-naive genotype-1 (GT1) hepatitis C virus (HCV) patients. The results from the SILEN-C3 and SILEN-C1 studies show that BI 201335 may have the potential to shorten the duration of...

2011-11-08 07:14:00

SAN FRANCISCO, Nov. 8, 2011 /PRNewswire/ --- By examining multiple-cause death records, researchers from the Centers for Disease Control and Prevention have determined that deaths from viral hepatitis are insufficiently appreciated and by 2007 were exceeding reported deaths caused by HIV. Approximately 21.8 million records were included in the study, which was presented at the annual meeting of the American Association for the Study of Liver Diseases on Tuesday, November 8. Those records...

2011-11-07 23:30:00

⢠Results add to data suggesting that SVR can be achieved with the combination of daclatasvir (BMS-790052) and asunaprevir (BMS-650032) in HCV genotype 1b patients ⢠Study expanded to include alfa/RBV ineligible or intolerant patients Princeton, NJ (PRWEB) November 07, 2011 Bristol-Myers Squibb Company (NYSE: BMY) today announced results from a ten patient sentinel cohort of an ongoing Phase II study in which treatment with a dual, all-oral...

2011-11-07 10:00:00

SAN FRANCISCO and RIDGEFIELD, Conn., Nov. 7, 2011 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced results from a planned interim analysis of a Phase 2b study, SOUND-C2, that showed the combination of two oral direct acting hepatitis C virus (HCV) compounds - the protease inhibitor BI 201335 and the polymerase inhibitor BI 207127 with ribavirin (RBV) - was successful in reducing viral load below the lower limit of quantifiable levels at week 12 (viral response) in...


Latest Hepatitis C/co-infection with HIV Reference Libraries

11_9e88d15808b8ecc3fcbbdfcf4ae75786
2011-01-20 19:23:30

Hepatitis C virus (HCV) is an enveloped, positive-sense single-stranded RNA virus of the family Flaviviridae. It consists of a core of genetic material surrounded by an icosahedra protective shell of protein. The genome consists of a single open reading frame that is 9600 nucleotide bases long. HCV replication takes several steps. It primarily replicates in the hepatocytes of the liver. It can also reproduce in peripheral blood mononuclear cells. There is a wide variety of genotypes and...

More Articles (1 articles) »